www.bloomberg.com
Dajun Yang, CEO of Ascentage Pharma, announced that the company’s partnership with Takeda on a blood cancer therapy could be ready for commercialization within two years. Speaking on “Bloomberg: The China Show” ahead of his presentation at the JPMorgan Healthcare Conference, Yang expressed optimism about the therapy’s timeline. Ascentage Pharma, co-founded by Yang, is collaborating with the pharmaceutical giant Takeda to develop this treatment for blood cancer. The news highlights an accelerated path to market for the promising therapy.
Read More
